Phosphoinositides: Older Than We First Thought?

The dairy fat paradox: Whole dairy products may be healthier than we thought

Differences across the June , 2014 and December , 2015 versions of How Important Are Sectoral Shocks ?

While the main results– first, that industry-specific shocks are more important than previously thought, accounting for more than half of aggregate volatility, and second, that this difference arises from past papers’imposition of unitary elasticities of substitution– of the two versions of How Important Are Sectoral Shocks? are the same, the way in which I arrive at these results are suffi cie...

Phosphoinositides. 2. The inositol 1-phosphate structure in liver phosphatidylinositol.

The hydrolysis studies reported in the preceding paper (Hawthorne, 1960) suggest that in liver phosphatidylinositol the phosphate group is linked to one of the cis-hydroxyl groups of the inositol, i.e. to positions 1(3)or 2-. Until recently, the inositol monophosphate isolated from phosphoinositides was believed to be optically inactive (Iselin, 1949; Hawthorne, 1955) and so liver phosphatidyli...

Identification of a phosphoinositide binding motif that mediates activation of mammalian and yeast phospholipase D isoenzymes.

Phosphoinositides are both substrates for second messenger-generating enzymes and spatially localized membrane signals that mediate vital steps in signal transduction, cytoskeletal regulation and membrane trafficking. Phosphatidylcholine-specific phospholipase D (PLD) activity is stimulated by phosphoinositides, but the mechanism and physiological requirement for such stimulation to promote PLD...

“How should we treat older patients with Metastatic Colorectal Cancer, A Review”

Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...